Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. - sprookjes - yvandenbroek - TriplyDB

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

http://www.wikidata.org/entity/Q34789118

about

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants How we treat bleeding associated with direct oral anticoagulants Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population The evolution of anticoagulant therapy Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?Protocol in managing oral surgical patients taking dabigatran Respiratory review of 2014: pulmonary thromboembolism The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years Pharmacological prevention of venous thromboembolism in orthopaedic surgery Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.The proof for new oral anticoagulants: clinical trial evidence.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.A Pilot Study Comparing Hospital Readmission Rates In Patients Receiving Rivaroxaban or Enoxaparin After Orthopedic Surgery.Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty.Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.Update in new medications for primary care.Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Thrombembolic complications after total ankle replacement.Edoxaban: an update on the new oral direct factor Xa inhibitor.Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.Thromboprophylaxis and orthopaedic surgery: options and current guidelines Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Pathways for venous thromboembolic prophylaxis in medical and surgical patients.

P2860

Q24632872-902435CC-C743-4BF2-9441-6390E52C3868 Q26741697-FEC9D366-E287-4F49-8508-E4535DCAB074 Q26748343-3B0A9810-2701-432F-94C3-DA57EA80886F Q26770402-BEDDE359-78B3-4553-B908-9B2C2521C9DE Q26771859-4FF0408A-E938-4470-97F9-EEFD8303E5DC Q26782931-2757D872-6494-41EA-8755-0B6C85089DB4 Q26828439-64A4F86D-B51E-4A8F-B7D6-25788B5896E8 Q26828817-B2A2E195-1557-4423-AA0E-0E8B88F1E373 Q26864411-D04F842F-4CB5-4667-966C-A4C769B51D75 Q26995635-D06035FB-E40E-42C4-BDAC-80A16B2EE699 Q27003914-388E3B69-14F7-432E-87FB-2FC5F04E300F Q27006890-1F90ADD4-D34D-4BB2-8EAA-98EEE0BFE548 Q27028131-51B05953-07D5-453D-9CEB-94E49212CA3E Q27497485-96393AC4-70F3-4564-AD7E-D2D8E3ADE2C4 Q27678539-D16E82C3-3ADD-4D94-BC49-26106F2CC6EF Q28072799-5C2EF831-D79E-42D1-BBE4-8BEF75A362C8 Q28082967-5E37B31B-EF16-4B48-889E-58A71E859BBB Q28083067-C890AF53-5FFC-4CA1-B59E-911BDA064E6B Q28250157-99A65E06-C43C-4AF3-B82A-3941C3C66499 Q28477868-0142BB27-80AA-4F48-AE10-6639ED8152EF Q30975631-94CEA559-DFA8-4749-BE9D-C03C10B9E680 Q33397016-6E6DDBFE-C4D3-46DA-BF1E-A5FE6F2FBBCD Q33397359-9DD53B80-98D1-4576-95EF-F4BC30FB4277 Q33402042-8F6297FE-1FFD-4A0F-9BE5-62287F12959F Q33433196-FDBCC391-951F-49E6-9C8C-E3E5F537DF19 Q33714792-D912F282-E99B-424D-80AD-56B38344E0AB Q33725111-A436E766-C1B8-412F-9D39-3D7E4E20FC69 Q33730845-941A06AA-1F7E-41E6-B6C8-BCF2E7E8B8A3 Q33823899-9F42789F-3C0B-4131-8C58-C1499D7D9D0D Q33854667-C22A8913-3FE9-4702-895B-7C174B9031EB Q33888679-D22084DF-CD04-4E37-9471-7FEF3EF4830D Q33935409-CB1EBFBA-70A6-4C05-8E12-C2BE2CCB11FE Q33984758-EF1C1FDA-004C-4826-9C4C-1DF789493BF0 Q34035190-4B6CC295-A2E7-41B9-B9E3-AC51D6FD2E4B Q34058973-5B2D8B38-1141-4B26-8B23-93B6856E6B1D Q34088870-3F889E89-F127-4ADD-999B-88C001B751C5 Q34175551-7C6A5CC5-9CF2-4017-93B4-9A6E1010577B Q34178148-900CD4E4-2140-4A66-8AB2-99CA85879CCB Q34252907-F4527705-BBEF-40A2-9B54-5F166C0116D3 Q34264223-16890391-CC5B-4A16-9AE1-C0A6C9A487CC

P2860

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

http://www.wikidata.org/entity/Q34789118

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@ast

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@en

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@nl

type

label

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@ast

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@en

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@nl

prefLabel

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@ast

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@en

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@nl

P1433

Q34789118-A56A0851-081D-4046-B5DE-EBE57D5B2631

P1476

Q34789118-90A81CEE-1350-4602-9D69-31990BD00D4D

P2093

Q34789118-0ED85440-423C-4D6A-8DB2-C06E80EF970D

Q34789118-31800CDE-587F-4491-A635-74497EBE41E3

Q34789118-4FEC6F4D-CE56-495D-880A-0FC00221148E

Q34789118-6811CFF8-A806-4273-A5F2-A8C8FF96A791

Q34789118-715EA41E-98A6-4E81-BD48-22D8903F07A9

Q34789118-9977E36C-E6E9-4469-BEA8-C0E96BD29983

Q34789118-B85F8A42-9B30-4DA5-B5F3-9B28ED600F65

Q34789118-E5957ADB-6A91-46D7-BF16-59C63E1145A7

Q34789118-F42A01C0-FFBF-488D-9773-6CD6955AA0E3

P304

Q34789118-8B1DD78E-9FFE-4F9F-B34C-9B14F9B66531

P31

Q34789118-082218AC-45E9-4EE9-A39E-A7343BBE75AE

P356

Q34789118-AE8CAFA8-B5D4-479C-9956-4F18DE89E2AF

P407

Q34789118-C1D0306C-4FD2-4496-9B73-CDB056027FB9

P433

Q34789118-7208576D-E77C-477D-8855-8D49FD6B4A20

P478

Q34789118-CE30FFB4-D6D8-4183-B428-56DB05354BCE

P577

Q34789118-3A728B6D-8D67-4464-BCFF-4BC16FCD8722

P698

Q34789118-70CB6CF4-3ECB-4AAE-9B18-D2B8DAEB8986

P356

P1433

The New England Journal of Medicine

P1476

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

@en

P2093

Alexander G G Turpie

http://www.w3.org/2001/XMLSchema#string

Frank Misselwitz

http://www.w3.org/2001/XMLSchema#string

Jay R Lieberman

http://www.w3.org/2001/XMLSchema#string

Lars C Borris

http://www.w3.org/2001/XMLSchema#string

Michael R Lassen

http://www.w3.org/2001/XMLSchema#string

Nadia Rosencher

http://www.w3.org/2001/XMLSchema#string

RECORD3 Investigators

http://www.w3.org/2001/XMLSchema#string

Tiemo J Bandel

http://www.w3.org/2001/XMLSchema#string

Walter Ageno

http://www.w3.org/2001/XMLSchema#string

P304

2776-2786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA076016

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18579812

http://www.w3.org/2001/XMLSchema#string